Vistusertib

Drug Overview

Vistusertib (formerly known as AZD2014) is an investigational, orally bioavailable, small-molecule inhibitor of the mammalian target of rapamycin (mTOR). Unlike earlier mTOR inhibitors (rapalogs) that primarily target only the mTORC1 complex, vistusertib is a dual mTORC1/mTORC2 inhibitor. This is a significant distinction because blocking mTORC2 prevents the “rebound” activation of the AKT pathway often seen with older drugs, potentially making it more effective at stopping cancer cell growth and inducing apoptosis.

In the clinical landscape of March 2026, vistusertib remains an investigational agent and is not currently FDA-approved. It is being evaluated across several Phase I and Phase II trials, particularly in combination with other anti-cancer agents for hormone receptor-positive breast cancer, ovarian cancer, and lung cancer.

• Generic Name: Vistusertib.
• Code Name: AZD2014.
• Drug Class: Dual mTORC1/mTORC2 Inhibitor; ATP-Competitive mTOR Inhibitor.
• Mechanism: Competitive inhibition of the ATP-binding site on the mTOR kinase.
• Route of Administration: Oral (Tablet/Capsule).
• FDA Status: Investigational. As of early 2026, it has not received regulatory approval for commercial use.

What Is It and How Does It Work? (Mechanism of Action)

Vistusertib is designed to be a more comprehensive “off-switch” for the PI3K/AKT/mTOR pathway, a major signaling network that cancer cells use to survive, grow, and resist treatment.

1. Dual Complex Inhibition

Most FDA-approved mTOR inhibitors (like everolimus) only inhibit mTORC1. When only mTORC1 is blocked, the cell often triggers mTORC2 to activate AKT, providing a workaround that allows the cancer to keep growing. Vistusertib inhibits both mTORC1 and mTORC2, effectively closing this escape route.

2. Molecular Level Mechanisms

1. ATP-Competitive Binding: Vistusertib competes with ATP (the cell’s energy currency) for the binding site on the mTOR enzyme. By occupying this site, it prevents the enzyme from functioning.
2. Reduction of Phosphorylation: It decreases the phosphorylation of downstream targets such as S6 ribosomal protein (an mTORC1 marker) and AKT at Ser473 (an mTORC2 marker).
3. Growth Arrest and Death: By silencing these signals, the drug halts the cell cycle and induces apoptosis (programmed cell death) in tumor cells that are addicted to this pathway.
4. Immune Modulation: 2026 research has also explored vistusertib’s ability to promote a pro-inflammatory “Th1” environment, potentially making it a useful partner for immunotherapy.

FDA Approved Clinical Indications

There are currently no FDA-approved indications for vistusertib.

Clinical research as of 2026 focuses on “unmet need” populations where standard therapies have failed:

• Hormone Receptor-Positive (HR+) Endometrial Cancer: Studied in combination with anastrozole for recurrent or metastatic cases.
• ER+ Breast Cancer: Investigated as a method to overcome endocrine therapy resistance.
• Platinum-Resistant Ovarian Cancer: Evaluated in combination with paclitaxel.
• Squamous Non-Small Cell Lung Cancer (sqNSCLC): Studied for its role in advanced or refractory disease.
• Muscle Invasive Bladder Cancer: Included in modular “Umbrella” trials (like BISCAY) in combination with immunotherapy.

Dosage and Administration Protocols

Because vistusertib is an investigational agent, dosing is strictly determined by specific clinical trial protocols. Researchers have focused on finding a balance between effectiveness and the metabolic side effects typical of mTOR inhibitors.

Clinical Efficacy and Research Results

As of March 2026, clinical results suggest that vistusertib is most effective when used as part of a “doublet” or “triplet” therapy.

• The VICTORIA Trial (Endometrial Cancer): Adding vistusertib to anastrozole improved the 8-week progression-free rate to 67.3% compared to 39.1% with anastrozole alone.
• Ovarian Cancer Synergy: In early trials, the combination of vistusertib and paclitaxel resulted in tumor shrinkage in 52% of patients with platinum-resistant high-grade serous ovarian cancer.
• Lung Cancer: In squamous NSCLC, response rates of approximately 35% have been observed in combination settings, though dose adjustments were often necessary to manage side effects.
• Lymphoma Limitations: The TORCH trial found that vistusertib was less effective than hoped for diffuse large B-cell lymphoma (DLBCL), suggesting that its future lies more in solid tumor combinations.

Safety Profile and Side Effects

Vistusertib shares many of the “class effects” associated with mTOR inhibition, primarily related to metabolism and mucosal health.

Common Side Effects (>20%):

• Fatigue: A consistent sense of tiredness reported across all trials.
• Nausea and Diarrhea: Generally manageable with supportive medications.
• Hyperglycemia: High blood sugar, as mTOR plays a key role in insulin signaling.
• Lymphopenia: A drop in the number of white blood cells (lymphocytes).

Serious Risks and Monitoring:

• Mucositis/Stomatitis: Painful mouth sores that can be a dose-limiting toxicity.
• Hypertension: Elevated blood pressure requiring regular monitoring.
• Elevated Liver Enzymes (AST/ALT): Requires periodic blood tests to ensure liver safety.
• Rash: Skin eruptions that are usually manageable but can require dose reductions.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, vistusertib is being used to study “Metabolic Reprogramming.” Cancer stem cells often use the mTOR pathway to remain “quiescent” (dormant), allowing them to survive chemotherapy. Researchers in 2026 are investigating if vistusertib can “wake up” these dormant cells or disrupt their metabolism to prevent tumor recurrence. Additionally, because mTOR is a key regulator of aging (senescence), scientists are exploring if dual mTOR inhibitors can influence the “stemness” of healthy cells during the regenerative process.

Patient Management and Practical Recommendations

Pre-treatment Tests:

• Baseline Glucose/A1c: Essential due to the high risk of hyperglycemia.
• Liver Function Panel: To check baseline AST/ALT levels.
• Cardiac Assessment: Monitoring blood pressure is a standard requirement.

“Do’s and Don’ts” List:

• DO monitor your blood sugar regularly if you have a history of diabetes or pre-diabetes.
• DO use alcohol-free mouthwashes and maintain good oral hygiene to prevent mouth sores.
• DON’T take strong CYP3A4 inhibitors/inducers (like St. John’s Wort or certain anti-seizure meds) as they can drastically change the drug’s levels in your body.
• DON’T ignore sudden onset of shortness of breath or cough, which can occasionally signal rare lung inflammation (pneumonitis).

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Vistusertib is an investigational agent and is not currently approved by the US FDA for any indication. Access is limited exclusively to registered clinical trials. Always consult with a qualified oncologist regarding your diagnosis and eligibility for research participation.